李林

    【摘要】 目的：探討抗程序性死亡因子(PD-1)/程序性死亡配体1(PD-L1)单抗治疗进展期非小细胞肺癌(NSCLC)患者的效果。方法：选取2020年6月-2021年6月于江西省肿瘤医院就诊的进展期NSCLC患者60例，按随机数字表法将其分为对照组(n=30)和观察组(n=30)。对照组给予多西他赛(DOC)治疗，观察组给予卡瑞利珠单抗治疗，比较两组近期疗效、肿瘤浸润T细胞(TITL)密度及分布情况、血清相关指标及不良反应发生情况。结果：治疗9周后，观察组疾病控制率(73.33%)较对照组(46.67%)高(P<0.05);观察组CD3+、CD4+、CD4+/CD8+均较对照组高，CD8+水平较对照组低(P<0.05);观察组基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)、角蛋白19片段抗原21-1(CYFRA21-1)水平均较对照组低(P<0.05);观察组不良反应发生率(13.33%)较对照组(36.67%)低(P<0.05)。结论：进展期NSCLC患者应用抗PD-1/PD-L1单抗治疗可改善肿瘤浸润T细胞密度及分布情况，抑制肿瘤生长转移及新生血管生成，提高临床疗效。

    【关键词】 多西他赛 非小细胞肺癌 卡瑞利珠单抗 程序性死亡配体1

    Effect of Anti-PD-1/PD-L1 mAb in the Treatment of Advanced Non-small Cell Lung Cancer/LI Lin. //Medical Innovation of China， 2022， 19(16)： 00-005

    [Abstract] Objective： To explore the effect of anti-programmed death factor (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibody in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Method： A total of 60 patients with advanced NSCLC who were treated in Jiangxi Cancer Hospital from June 2020 to June 2021 were selected. They were divided into control group (n=30) and observation group (n=30) according to the random number table method. The control group was treated with Docetaxel (DOC) ......